ULBI Ultralife

Ultralife Corporation Files Form 12b-25 Notification of Late Filing

Ultralife Corporation Files Form 12b-25 Notification of Late Filing

NEWARK, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Ultralife Corporation (NASDAQ: ULBI), today announced that it has filed a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission in connection with its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

The extension is necessary to allow for the completion of the accounting close and financial results audit of Electrochem Solutions, Inc., which the Company acquired on October 31, 2024. The Company expects to file its Form 10-K with the Securities and Exchange Commission as soon as practicable, and no later than April 1, 2025, in accordance with Rule 12b-25.

In addition, the Company will reschedule its earnings release and conference call for the fourth quarter and fiscal year 2024, previously scheduled for Tuesday, March 11, 2025, and announce the date and time of the rescheduled earnings release and call once the filing date of its Form 10-K is confirmed. 

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit .

Company Contact:

Ultralife Corporation

Philip A. Fain

(315) 210-6110

Investor Relations Contact:

Alliance Advisors IR

Jody Burfening/Alex Villalta

(212) 838-3777







EN
07/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultralife

Ultralife Corp: 1 director

A director at Ultralife Corp bought 53,000 shares at 5.677USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch